# Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

> **NCT05857085** · PHASE4 · COMPLETED · sponsor: **General and Teaching Hospital Celje** · enrollment: 90 (actual)

## Conditions studied

- Endothelial Dysfunction
- Diabetes Mellitus, Type 1
- Biomarkers
- Endothelial Progenitor Cells
- SGLT 2 Inhibitors
- Incretins
- Glucose Excursions
- FMD
- FPF
- Arterial Stiffness

## Interventions

- **DRUG:** Semaglutide Pen Injector [Ozempic]
- **DRUG:** Empagliflozin 10 MG

## Key facts

- **NCT ID:** NCT05857085
- **Lead sponsor:** General and Teaching Hospital Celje
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-15
- **Primary completion:** 2022-03-10
- **Final completion:** 2023-04-20
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05857085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05857085, "Novel Therapeutics and Endothelial Dysfunction in T1DM Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05857085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*